<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151484">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02081989</url>
  </required_header>
  <id_info>
    <org_study_id>CP-01/13</org_study_id>
    <secondary_id>256/13</secondary_id>
    <nct_id>NCT02081989</nct_id>
  </id_info>
  <brief_title>Renal Denervation in Diabetes.</brief_title>
  <official_title>Effect of Renal Sympathetic Denervation on Glycemic Status Independent of Blood Pressure-lowering.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart Foundation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal denervation (the use of radio waves to oblate the renal artery) has been shown to be
      an effective treatment for high blood pressure. It is currently being tested in heart
      failure patients and we would now like to look it its effects on diabetes.

      We therefore plan to enrol 20 participants with type II diabetes into this study.  Half will
      undergo renal denervation in addition to their standard care and the other half will act as
      controls and only receive standard care.  Treatment allocation will be randomly assigned.

      All participants will undergo screening (including a physical exam, blood tests, ultrasounds
      and a muscle biopsy).  All patients will have follow up tests (including physical exams and
      blood tests) 1, 3 and 6 months later.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in glycemic control at 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glucose uptake into peripheral skeletal muscle</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess glucose uptake into peripheral skeletal muscle</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renal denervation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group - no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal denervation</intervention_name>
    <description>Renal denervation</description>
    <arm_group_label>Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years

          -  Able and willing to provide informed consent

          -  Patients with established type II diabetes mellitus (HbA1C&gt;7%, diet or oral
             hypoglycaemic agents)

          -  Clinical stable as demonstrated by no change in background anti-diabetic medication
             in the last 30 days.

          -  Anticipated that patients are able to maintain a stable dose of medication for the
             duration of the study

        Exclusion Criteria:

          -  Renal arterial anatomy ineligible for RDN: main renal arteries &lt;4 mm in diameter or
             &lt;20 mm in treatable length; multiple renal arteries where main renal artery is
             estimated to supply &lt;75% of the kidney; haemodynamically or anatomically significant
             renal artery abnormality or stenosis in either renal artery which, in the
             investigator's opinion, would interfere with safe cannulation of the renal artery or
             require surgical repair or interventional dilation

          -  History of prior renal artery intervention including balloon angioplasty, stenting or
             previous renal denervation.

          -  Single functioning kidney

          -  Need for insulin (interferes with euglycemic clamp testing) or GLP-I analogues

          -  eGFR &lt;30 ml/min (MDRD formula)

          -  Any medical condition which, in the investigators opinion, may adversely affect the
             participants safety in the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Krum, MBBS, FRACP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University / Alfred Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henry Krum, MBBS, FRACP, PhD</last_name>
    <phone>+61 3 9903 0042</phone>
    <email>henry.krum@monash.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marina Skiba, Bed(sec)Sci</last_name>
    <phone>+61 3 9076 8546</phone>
    <email>marina.skiba@monash.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henry Krum, MBBS, FRACP, PhD</last_name>
      <phone>+61 3 9903 0042</phone>
      <email>henry.krum@monash.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marina Skiba, Bed(sec)Sci</last_name>
      <phone>+61 3 9076 8546</phone>
      <email>marina.skiba@monash.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Henry Krum, MBBS, FRACP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>March 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Monash University</investigator_affiliation>
    <investigator_full_name>Prof Henry Krum</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Renal denervation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
